Exenatide

GLP-1 Receptor Agonist — ALIMENTARY TRACT AND METABOLISM

Key facts

Exenatide is a drug in the GLP-1 Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2005. Its mechanism of action is classified as Glucagon-like Peptide-1 (GLP-1) Agonists. DrugCentral lists 2 molecular targets, including Glp1r and GLP1R. Recorded indications include Type 2 Diabetes Mellitus Treatment Adjunct.

• Drug class: GLP-1 Receptor Agonist.
• Mechanism of action: Glucagon-like Peptide-1 (GLP-1) Agonists.
• Molecular targets: Glp1r and GLP1R (2 listed in DrugCentral).
• Indications: Type 2 Diabetes Mellitus Treatment Adjunct.
• ATC code: A10BJ01 (Glucagon-like peptide-1 (GLP-1) analogues).
• Molecular formula: C184H282N50O60S; molecular weight 4186.63 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Type 2 Diabetes Mellitus Treatment Adjunct

Contraindications (13)

• Acute nephropathy
• Acute vomiting
• Alcoholism
• Calculus in biliary tract
• Chronic renal failure syndrome
• Dehydration
• Gastroparesis
• Hypertensive disorder
• Hypoglycemic disorder
• Impaired renal function disorder
• Pancreatitis
• Severe diarrhea
• Transplant of kidney

Mechanism & targets

• Mechanism of action (MoA): Glucagon-like Peptide-1 (GLP-1) Agonists
• Established pharmacologic class: GLP-1 Receptor Agonist

Molecular targets (2)

Target	Gene	Action	Activity
Glucagon-like peptide 1 receptor	Glp1r	unknown	IC50 9.85
Glucagon-like peptide 1 receptor	GLP1R	agonist	IC50 9.18

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2005-04-28	FDA	—	ASTRAZENECA AB

ATC classification

ATC code	Therapeutic hierarchy
A10BJ01	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Glucagon-like peptide-1 (GLP-1) analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Pancreatitis	3933.6
Blood glucose increased	3283.5
Weight decreased	1867.9
Injection site nodule	1621.6
Pancreatitis acute	916.6
Blood glucose decreased	865.5
Nausea	835.6
Injection site haemorrhage	763.1
Device leakage	686.2
Incorrect dose administered by device	647.8
Glycosylated haemoglobin increased	636.4
Injection site mass	636.3

Chemical structure

• Molecular formula: C₁₈₄H₂₈₂N₅₀O₆₀S
• Molecular weight: 4186.63 g/mol
• CAS number: 141758-74-9
• InChIKey: HTQBXNHDCUEHJF-XWLPCZSASA-N
• PubChem CID: 45588096

CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Exenatide used for?

DrugCentral lists the following indications for Exenatide: Type 2 Diabetes Mellitus Treatment Adjunct.

How does Exenatide work?

Exenatide is classified as Glucagon-like Peptide-1 (GLP-1) Agonists; its molecular targets in DrugCentral include Glp1r and GLP1R (agonist).

When was Exenatide first approved?

Exenatide was first approved by the FDA in 2005.

What drug class does Exenatide belong to?

Exenatide is in the GLP-1 Receptor Agonist class.

What is the chemical formula of Exenatide?

Exenatide has the molecular formula C184H282N50O60S and a molecular weight of 4186.63 g/mol.

Sources

• DrugCentral drug card 1123 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL414357 — compound record and bioactivity
• PubChem CID 45588096 — chemical identifiers
• DrugBank DB01276 — drug record
• FDA UNII 9P1872D4OL — substance identity
• DailyMed: FDA labels for Exenatide — current prescribing information (label search)
• UniProt P43220 (GLP1R) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.